Summary
Regeneron Pharmaceuticals, Inc. filed a Current Report on Form 8-K on January 24, 2001, to announce its operating results for the fourth quarter and the full year ended December 31, 2000. The report primarily serves to attach the press release containing these financial and operational updates. Investors would look to this filing for the company's performance metrics as of the end of the fiscal year 2000.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 24, 2001.
- 2The filing's primary purpose was to announce the company's operating results.
- 3The results covered the fourth quarter and the full fiscal year ended December 31, 2000.
- 4Exhibit 99.1, a press release dated January 25, 2001, contains the detailed operating results.
- 5This filing provides an update on the company's financial performance at the close of the year 2000.
- 6The report does not contain any other material events or financial statements beyond the press release.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce Regeneron Pharmaceuticals, Inc.'s operating results for the fourth quarter and the full year ended December 31, 2000. This is done by attaching the press release containing these results as an exhibit.
The detailed operating results are provided in the press release, dated January 25, 2001, which is attached as Exhibit 99.1 to this 8-K filing.
Based on the provided content, this 8-K filing is solely focused on announcing the company's operating results for the fourth quarter and year-end 2000. Items 1-4 and Item 8 are marked as 'Not applicable,' indicating no other material events or changes are reported in this specific filing.